Jefferies analyst Michael Leuchten assumed coverage of Novartis (NVS) with a Hold rating and CHF 110 price target While Novartis is facing meaningful patent expiries throughout the decade, there is “more replacement power than is appreciated by consensus,” but this seems already reflected in the valuation, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Cautious Hold Rating on Novartis AG Amid Mixed ianalumab Study Results and Uncertain Growth Prospects
- Novartis to Acquire Avidity Biosciences, Enhancing Neuroscience Pipeline
- M&A News: Novartis to Acquire Avidity Biosciences in $12B Deal
- Novartis agrees to acquire Avidity for $72 per share in cash
- Novartis close to deal to buy Avidity for over $70 per share, Bloomberg says